U.S. Capital Wealth Advisors’s Viking Therapeutics VKTX Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.17M	Sell	66,780 -2,250	-3%	-$72.3K	0.05%	335
2025 Q4	$2.43M	Sell	69,030 -25,135	-27%	-$891K	0.06%	297
2025 Q3	$2.47M	Buy	94,165 +30,619	+48%	+$913K	0.07%	284
2025 Q2	$1.68M	Buy	63,546 +27,795	+78%	+$732K	0.05%	329
2025 Q1	$863K	Sell	35,751 -8,423	-19%	-$266K	0.03%	455
2024 Q4	$1.78M	Buy	44,174 +21,129	+92%	+$1.2M	0.06%	324
2024 Q3	$1.46M	Buy	23,045 +15,820	+219%	+$928K	0.05%	301
2024 Q2	$383K	Buy	+7,225	New	+$474K	0.01%	509

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

U.S. Capital Wealth Advisors's VKTX Position: Q1 2026 in Review

U.S. Capital Wealth Advisors reduced its Viking Therapeutics (VKTX) stake by 3.3% in Q1 2026, selling an estimated $72.3K and leaving 66,780 shares worth $2.17M. The position accounts for 0.05% of the portfolio, ranked #335.

U.S. Capital Wealth Advisors first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.47M in Q3 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

U.S. Capital Wealth Advisors held 66,780 shares of Viking Therapeutics worth $2.17M as of Q1 2026.
U.S. Capital Wealth Advisors sold 2,250 Viking Therapeutics shares in Q1 2026, an estimated $72.3K.
Viking Therapeutics made up 0.05% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #335 holding.
U.S. Capital Wealth Advisors first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
U.S. Capital Wealth Advisors's Viking Therapeutics position peaked at $2.47M in Q3 2025.
413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.